Related references
Note: Only part of the references are listed.Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials
Masayoshi Harigai et al.
MODERN RHEUMATOLOGY (2020)
Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare
William Damsky et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Efficacy and safety of topical delgocitinib in patients with chronic hand eczema: data from a randomized, double-blind, vehicle-controlled phase IIa study
M. Worm et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Open-label pilot study of tofacitinib 2% for the treatment of refractory vitiligo
P. Mobasher et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb
Andreas Wollenberg et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)
Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study
Emma Guttman-Yassky et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations
Henrik M. Hammaren et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)
Successful treatment of extensive calcifications and acute pulmonary involvement in dermatomyositis with the Janus-Kinase inhibitor tofacitinib - A report of two cases
Sarah Wendel et al.
JOURNAL OF AUTOIMMUNITY (2019)
The Use of Janus Kinase Inhibitors in Vitiligo: A Review of the Literature
Nicole Relke et al.
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY (2019)
JAK inhibitors for alopecia areata: a systematic review and meta-analysis
K. Phan et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2019)
JAK inhibitors and alopecia areata
Amos Gilhar et al.
LANCET (2019)
PF-06651600, a Dual JAK3/TEC Family Kinase Inhibitor
Hua Xu et al.
ACS CHEMICAL BIOLOGY (2019)
Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease
Christopher Ma et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)
Baricitinib for the treatment of rheumatoid arthritis and systemic lupus erythematosus: a 2019 update
Satoshi Kubo et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2019)
Successful treatment of cheilitis granulomatosa with lenalidomide
F. Solimani et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2019)
Tofacitinib modulates the VZV-specific CD4+ T cell immune response in vitro in lymphocytes of patients with rheumatoid arthritis
Giovanni Almanzar et al.
RHEUMATOLOGY (2019)
Dynamics of body mass index and visceral adiposity index in patients with rheumatoid arthritis treated with tofacitinib
Diana S. Novikova et al.
RHEUMATOLOGY INTERNATIONAL (2019)
T cell pathology in skin inflammation
Robert Sabat et al.
SEMINARS IN IMMUNOPATHOLOGY (2019)
Current Status in the Discovery of Covalent Janus Kinase 3 (JAK3) Inhibitors
Jun Dai et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2019)
Tofacitinib in Amyopathic Dermatomyositis-Associated Interstitial Lung Disease
Zhiwei Chen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Pemphigus: Current and Future Therapeutic Strategies
Dario Didona et al.
FRONTIERS IN IMMUNOLOGY (2019)
Therapeutic Targeting of Th17/Tc17 Cells Leads to Clinical Improvement of Lichen Planus
Farzan Solimani et al.
FRONTIERS IN IMMUNOLOGY (2019)
IFN-γ enhances cell-mediated cytotoxicity against keratinocytes via JAK2/STAT1 in lichen planus
Shuai Shao et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases
Kata P. Szilveszter et al.
FRONTIERS IN IMMUNOLOGY (2019)
Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World Data from the St. Gallen and Aarau Cohorts
Ruediger B. Mueller et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent
Alessia Alunno et al.
CELLS (2019)
JAK Inhibitors for Atopic Dermatitis: An Update
Helen He et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2019)
Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials
William J. Sandborn et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Nawaf Almutairi et al.
DERMATOLOGY (2019)
Follicular penetration of nanocarriers is an important penetration pathway for topically applied drugs
J. Lademann et al.
HAUTARZT (2019)
Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata
S. C. Gordon et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2019)
Risk for Herpes Zoster in Tofacitinib-Treated Rheumatoid Arthritis Patients With and Without Concomitant Methotrexate and Glucocorticoids
Jeffrey R. Curtis et al.
ARTHRITIS CARE & RESEARCH (2019)
Single Cell Based Phosphorylation Profiling Identifies Alterations in Toll-Like Receptor 7 and 9 Signaling in Patients With Primary Sjogren's Syndrome
Richard Davies et al.
FRONTIERS IN IMMUNOLOGY (2019)
Safety and efficacy of tofacitinib for up to 9.5years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study
Juergen Wollenhaupt et al.
ARTHRITIS RESEARCH & THERAPY (2019)
Expression Patterns of TNFα, MAdCAM1, and STAT3 in Intestinal and Skin Manifestations of Inflammatory Bowel Disease
Stephan R. Vavricka et al.
JOURNAL OF CROHNS & COLITIS (2018)
Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study
F. Valenzuela et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Successful therapy for pyoderma gangrenosum with a Janus kinase 2 inhibitor
S. Nasifoglu et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteers
Kent J. Weinhold et al.
CLINICAL IMMUNOLOGY (2018)
Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?
Ian C. Scott et al.
DRUG SAFETY (2018)
Aberrant cell signalling in PBMCs upon IFN- stimulation in primary Sjogren's syndrome patients associates with type I interferon signature
Richard Davies et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2018)
A review of the mechanisms of action of dimethylfumarate in the treatment of psoriasis
Juergen Brueck et al.
EXPERIMENTAL DERMATOLOGY (2018)
Herpes Zoster in Patients Receiving JAK Inhibitors For Ulcerative Colitis: Mechanism, Epidemiology, Management, and Prevention
Jean-Frederic Colombel
INFLAMMATORY BOWEL DISEASES (2018)
TH1/TH17 cell recognition of desmoglein 3 and bullous pemphigoid antigen 180 in patients with lichen planus
Thomas Schmidt et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2018)
Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study
Kenji Kabashima et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2018)
JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies
Gina A. Montealegre Sanchez et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE-052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis
Hidemi Nakagawa et al.
JOURNAL OF DERMATOLOGY (2018)
An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis
A. Jabbari et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)
Genome-Wide MicroRNA Analysis Implicates miR-30b/d in the Etiology of Alopecia Areata
Aylar Tafazzoli et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)
Development, Optimization, and Structure-Activity Relationships of Covalent-Reversible JAK3 Inhibitors Based on a Tricyclic Imidazo[5,4-d]pyrrolo[2,3-b]pyridine Scaffold
Michael Forster et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Identification of N-{cis-3-(Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)aminolcyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases
Michael L. Vazquez et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE)
Eric L. Simpson et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Topical Janus kinase inhibitors: A review of applications in dermatology
Anna-Marie Hosking et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
The use of JAK inhibitors in the treatment of progressive systemic sclerosis
S. C. Deverapalli et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2018)
Immune response patterns in non-communicable inflammatory skin diseases
K. Eyerich et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2018)
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
Daniel J. Wallace et al.
LANCET (2018)
Case report: successful treatment of refractory SAPHO syndrome with the JAK inhibitor tofacitinib
Qiao Yang et al.
MEDICINE (2018)
Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis
Kazuhiro Kurasawa et al.
RHEUMATOLOGY (2018)
Translocation of a gut pathobiont drives autoimmunity in mice and humans
S. Manfredo Vieira et al.
SCIENCE (2018)
Are Janus Kinase Inhibitors Superior over Classic Biologic Agents in RA Patients?
Przemyslaw J. Kotyla
BIOMED RESEARCH INTERNATIONAL (2018)
Gene Expression Profiling in Behcet's Disease Indicates an Autoimmune Component in the Pathogenesis of the Disease an Opens New Avenues for Targeted Therapy
Antonio Puccetti et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2018)
Achieving Hidradenitis Suppurativa Response Score is Associated with Significant Improvement in Clinical and Patient-reported Outcomes: Post Hoc Analysis of Pooled Data From PIONEER I and II
Alexandra Boer Kimball et al.
ACTA DERMATO-VENEREOLOGICA (2018)
Tofacitinib as the potent treatment for refractory pemphigus: A possible alternative treatment for pemphigus
Soheil Tavakolpour
DERMATOLOGIC THERAPY (2018)
Tofacitinib for the treatment of lichen planopilaris: A case series
Christine C. Yang et al.
DERMATOLOGIC THERAPY (2018)
Targeted Therapies for Autoimmune Bullous Diseases: Current Status
Kyle T. Amber et al.
DRUGS (2018)
Classification and management of adult inflammatory myopathies
Albert Selva-O'Callaghan et al.
LANCET NEUROLOGY (2018)
Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis
Kim Papp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Treatment of Mucous Membrane Pemphigoid With Janus Kinase Inhibitor Baricitinib
Stephanie Sarny et al.
JAMA OPHTHALMOLOGY (2018)
Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)
Nikolas von Bubnoff et al.
BMC CANCER (2018)
Tofacitinib Treatment and Molecular Analysis of Cutaneous Sarcoidosis
William Damsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Response of Dermatomyositis with Lung Involvement to a Janus Kinase Inhibitor Treatment
J. Hornig et al.
ZEITSCHRIFT FUR RHEUMATOLOGIE (2018)
Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors
Abril Verden et al.
DRUG SAFETY (2018)
Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients
Hanna Kim et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Ruxolitinib-associated infections: A systematic review and meta-analysis
Federico Lussana et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
The pathogenesis of dermatomyositis
C. Thompson et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis
Simon Tarp et al.
RHEUMATOLOGY (2017)
Hidradenitis Suppurativa Advances in Diagnosis and Treatment
Ditte Marie Lindhardt Saunte et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march
Tali Czarnowicki et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis
Robert Wolk et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2017)
The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A Phase 3, randomized, double-blind, placebo-controlled study
JianZhong Zhang et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2017)
Nickel Sulfate Promotes IL-17A Producing CD4+T Cells by an IL-23-Dependent Mechanism Regulated by TLR4 and Jak-STAT Pathways
Rami Bechara et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2017)
Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
Lucy Y. Liu et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure
Lucy Y. Liu et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis
Joseph F. Merola et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Tofacitinib for the treatment of alopecia areata and variants in adolescents
Brittany G. Craiglow et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata
Cheryl B. Bayart et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib
Brooke Rothstein et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial
Roy Fleischmann et al.
LANCET (2017)
Expression of the JAK/STAT Signaling Pathway in Bullous Pemphigoid and Dermatitis Herpetiformis
K. Juczynska et al.
MEDIATORS OF INFLAMMATION (2017)
The emerging safety profile of JAK inhibitors in rheumatic disease
Kevin L. Winthrop
NATURE REVIEWS RHEUMATOLOGY (2017)
Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors
Dafna Gladman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Maurizio Mennini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
Peter C. Taylor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Managing side effects of JAK inhibitors for myelofibrosis in clinical practice
Iram Saeed et al.
EXPERT REVIEW OF HEMATOLOGY (2017)
Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis
Debomita Chakraborty et al.
NATURE COMMUNICATIONS (2017)
A study on the risk of fungal infection with tofacitinib (CP-690550), a novel oral agent for rheumatoid arthritis
Yong Chen et al.
SCIENTIFIC REPORTS (2017)
A rare IL33 loss-of-function mutation reduces blood eosinophil counts and protects from asthma
Dirk Smith et al.
PLOS GENETICS (2017)
The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial
Kevin L. Winthrop et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Identification of Jak-STAT signaling involvement in sarcoidosis severity via a novel microRNA-regulated peripheral blood mononuclear cell gene signature
Tong Zhou et al.
SCIENTIFIC REPORTS (2017)
Tofacitinib restores the inhibition of reverse cholesterol transport induced by inflammation: understanding the lipid paradox associated with rheumatoid arthritis
S. Perez-Baos et al.
BRITISH JOURNAL OF PHARMACOLOGY (2017)
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials
Stanley B. Cohen et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Targeting JAK/STAT signalling in inflammatory skin diseases with small molecule inhibitors
Katharina Welsch et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2017)
Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis
K. L. Winthrop et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme
Jeffrey R. Curtis et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Lupus erythematosus revisited
Annegret Kuhn et al.
SEMINARS IN IMMUNOPATHOLOGY (2016)
Cutaneous immunology: basics and new concepts
Amir S. Yazdi et al.
SEMINARS IN IMMUNOPATHOLOGY (2016)
Development of Th17-Associated Interstitial Kidney Inflammation in Lupus-Prone Mice Lacking the Gene Encoding STAT-1
Gloria Yiu et al.
ARTHRITIS & RHEUMATOLOGY (2016)
Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis
Jeffrey R. Curtis et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study
V. J. Ludbrook et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum
J. L. Blok et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis
K. A. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial
R. Bissonnette et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
Recent advances in dermatomyositis-specific autoantibodies
Manabu Fujimoto et al.
CURRENT OPINION IN RHEUMATOLOGY (2016)
Antibiotic Treatment of Hidradenitis Suppurativa
Vincenzo Bettoli et al.
DERMATOLOGIC CLINICS (2016)
A Regulatory Feedback between Plasmacytoid Dendritic Cells and Regulatory B Cells Is Aberrant in Systemic Lupus Erythematosus
Madhvi Menon et al.
IMMUNITY (2016)
Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study
James Krueger et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2016)
Cellular and molecular immunologic mechanisms in patients with atopic dermatitis
Thomas Werfel et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2016)
A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis
Robert Bissonnette et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2016)
STAT3 Signaling in B Cells Is Critical for Germinal Center Maintenance and Contributes to the Pathogenesis of Murine Models of Lupus
Chuanlin Ding et al.
JOURNAL OF IMMUNOLOGY (2016)
Intrinsic Defect in Keratinocyte Function Leads to Inflammation in Hidradenitis Suppurativa
Claire Hotz et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2016)
Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus
L. Kahl et al.
LUPUS (2016)
New insights into the immunopathogenesis of systemic lupus erythematosus
George C. Tsokos et al.
NATURE REVIEWS RHEUMATOLOGY (2016)
Tofacitinib Citrate for Refractory Cutaneous Dermatomyositis: An Alternative Treatment
Drew J. B. Kurtzman et al.
JAMA DERMATOLOGY (2016)
JAK3 as an Emerging Target for Topical Treatment of Inflammatory Skin Diseases
Ana Karina Alves de Medeiros et al.
PLOS ONE (2016)
Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial
Kim A. Papp et al.
BMC DERMATOLOGY (2016)
Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
Milene Kennedy Crispin et al.
JCI INSIGHT (2016)
Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata
Julian Mackay-Wiggan et al.
JCI INSIGHT (2016)
Selective JAK3 Inhibitors with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding Pocket
Michael Forster et al.
CELL CHEMICAL BIOLOGY (2016)
The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
John J. O'Shea et al.
ANNUAL REVIEW OF MEDICINE, VOL 66 (2015)
The genetics of pyoderma gangrenosum and implications for treatment: a systematic review
E. M. DeFilippis et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis
K. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial
R. Bissonnette et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials
K. A. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Pharmacologic Inhibition of JAK1/JAK2 Signaling Reduces Experimental Murine Acute GVHD While Preserving GVT Effects
Cristiana Carniti et al.
CLINICAL CANCER RESEARCH (2015)
Ultraviolet light converts propranolol, a nonselective β-blocker and potential lupus-inducing drug, into a proinflammatory AhR ligand
Karim Dorgham et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2015)
Targeted deep sequencing identifies rare loss-of-function variants in IFNGR1 for risk of atopic dermatitis complicated by eczema herpeticum
Li Gao et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2015)
The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling
Wataru Amano et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2015)
The immunogenetics of Behcet's disease: A comprehensive review
Masaki Takeuchi et al.
JOURNAL OF AUTOIMMUNITY (2015)
Human TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndrome
Alexandra Y. Kreins et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Simvastatin Prevents and Reverses Depigmentation in a Mouse Model of Vitiligo
Priti Agarwal et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)
Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate
Lauren L. Levy et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial
Herve Bachelez et al.
LANCET (2015)
Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey
R. Zeiser et al.
LEUKEMIA (2015)
The role of the IL-33/IL-1RL1 axis in mast cell and basophil activation in allergic disorders
Rohit Saluja et al.
MOLECULAR IMMUNOLOGY (2015)
Clinical improvement in psoriasis with specific targeting of interleukin-23
Tamara Kopp et al.
NATURE (2015)
Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials
Vibeke Strand et al.
ARTHRITIS RESEARCH & THERAPY (2015)
Activation of the JAK/STAT pathway in Behcet's disease
A. Tulunay et al.
GENES AND IMMUNITY (2015)
Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo
Atsuo Tanimoto et al.
INFLAMMATION RESEARCH (2015)
Topically Administered Janus-Kinase Inhibitors Tofacitinib and Oclacitinib Display Impressive Antipruritic and Anti-Inflammatory Responses in a Model of Allergic Dermatitis
Tomoki Fukuyama et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2015)
Immunology of Psoriasis
Michelle A. Lowes et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 32 (2014)
Diverse T-cell responses characterize the different manifestations of cutaneous graft-versus-host disease
Marie-Charlotte Brueggen et al.
BLOOD (2014)
Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease
Silvia Spoerl et al.
BLOOD (2014)
The Pharmacokinetics, Pharmacodynamics, and Safety of Baricitinib, an Oral JAK 1/2 Inhibitor, in Healthy Volunteers
Jack G. Shi et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Tofacitinib Suppresses Antibody Responses to Protein Therapeutics in Murine Hosts
Masanori Onda et al.
JOURNAL OF IMMUNOLOGY (2014)
Inhibition of TYK2 and JAK1 Ameliorates Imiquimod-Induced Psoriasis-like Dermatitis by Inhibiting IL-22 and the IL-23/IL-17 Axis
Melissa G. Works et al.
JOURNAL OF IMMUNOLOGY (2014)
Reversal of CD8 T-Cell-Mediated Mucocutaneous Graft-Versus-Host-Like Disease by the JAK Inhibitor Tofacitinib
Naoko Okiyama et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2014)
Systemic lupus erythematosus
Larissa Lisnevskaia et al.
LANCET (2014)
Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
Luzhou Xing et al.
NATURE MEDICINE (2014)
Remission of Recalcitrant Dermatomyositis Treated with Ruxolitinib
Thorsten Hornung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Potential pathogenetic role of Th17, Th0, and Th2 cells in erosive and reticular oral lichen planus
M-P Piccinni et al.
ORAL DISEASES (2014)
CXCL10 Is Critical for the Progression and Maintenance of Depigmentation in a Mouse Model of Vitiligo
Mehdi Rashighi et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis
Kevin L. Winthrop et al.
ARTHRITIS & RHEUMATOLOGY (2014)
Diagnosis and Treatment of Lichen Sclerosus An Update
Susanna K. Fistarol et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2013)
A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis
W. C. Ports et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
Decreased microRNA(miR)-145 and increased miR-224 expression in T cells from patients with systemic lupus erythematosus involved in lupus immunopathogenesis
M-C. Lu et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2013)
Cutting Edge: STAT1 Is Required for IL-6-Mediated Bcl6 Induction for Early Follicular Helper Cell Differentiation
Youn Soo Choi et al.
JOURNAL OF IMMUNOLOGY (2013)
Immunoexpression of Interleukin-22 and Interleukin-23 in Oral and Cutaneous Lichen Planus Lesions: A Preliminary Study
Jun Chen et al.
MEDIATORS OF INFLAMMATION (2013)
Effects of the Janus Kinase Inhibitor CP-690550 (Tofacitinib) in a Rat Model of Oxazolone-Induced Chronic Dermatitis
Yasutomo Fujii et al.
PHARMACOLOGY (2013)
Drug Delivery with Topically Applied Nanoparticles: Science Fiction or Reality?
J. Lademann et al.
SKIN PHARMACOLOGY AND PHYSIOLOGY (2013)
IFNγR signaling mediates alloreactive T-cell trafficking and GVHD
Jaebok Choi et al.
BLOOD (2012)
Functional STAT3 deficiency compromises the generation of human T follicular helper cells
Cindy S. Ma et al.
BLOOD (2012)
Possible role of interleukin-17 in the pathogenesis of lichen planus
O. Shaker et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
A Mouse Model of Vitiligo with Focused Epidermal Depigmentation Requires IFN-γ for Autoreactive CD8+ T-Cell Accumulation in the Skin
John E. Harris et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2012)
An Autoimmune Phenotype in Vulvar Lichen Sclerosus and Lichen Planus: A Th1 Response and High Levels of MicroRNA-155
Annelinde Terlou et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2012)
Graft-versus-host disease Part I. Pathogenesis and clinical manifestations of graft-versus-host disease
Sharon R. Hymes et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2012)
Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis
Naresh Punwani et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2012)
Medical Progress Alopecia Areata
Amos Gilhar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
Ronald F. van Vollenhoven et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Lichen Planus
Laurence Le Cleach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Tofacitinib (CP-690,550), a Janus Kinase Inhibitor for Dry Eye Disease
Shiao Hui (Melissa) Liew et al.
OPHTHALMOLOGY (2012)
Deficiency of IL-22 Contributes to a Chronic Inflammatory Disease: Pathogenetic Mechanisms in Acne Inversa
Kerstin Wolk et al.
JOURNAL OF IMMUNOLOGY (2011)
Involvement of Tyrosine Kinase-2 in Both the IL-12/Th1 and IL-23/Th17 Axes In Vivo
Masayuki Ishizaki et al.
JOURNAL OF IMMUNOLOGY (2011)
Depletion of Autoreactive Plasma Cells and Treatment of Lupus Nephritis in Mice Using CEP-33779, a Novel, Orally Active, Selective Inhibitor of JAK2
Lily D. Lu et al.
JOURNAL OF IMMUNOLOGY (2011)
Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)
Kamran Ghoreschi et al.
JOURNAL OF IMMUNOLOGY (2011)
Comorbidity profiles among patients with alopecia areata: The importance of onset age, a nationwide population-based study
Szu-Ying Chu et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2011)
The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures
S. M. MCHUGH et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2010)
Genome-wide association study in alopecia areata implicates both innate and adaptive immunity
Lynn Petukhova et al.
NATURE (2010)
Genetic susceptibility to systemic lupus erythematosus in the genomic era
Yun Deng et al.
NATURE REVIEWS RHEUMATOLOGY (2010)
γ-Secretase Gene Mutations in Familial Acne Inversa
Baoxi Wang et al.
SCIENCE (2010)
Activation of the Interferon-γ Signaling Pathway in Systemic Lupus Erythematosus Peripheral Blood Mononuclear Cells
Thomas Karonitsch et al.
ARTHRITIS AND RHEUMATISM (2009)
Janus kinases in immune cell signaling
Kamran Ghoreschi et al.
IMMUNOLOGICAL REVIEWS (2009)
History of atopy or autoimmunity increases risk of alopecia areata
Nazila Barahmani et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2009)
Selectivity and therapeutic inhibition of kinases: to be or not to be?
Kamran Ghoreschi et al.
NATURE IMMUNOLOGY (2009)
Vitiligo
Alain Taieb et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
PUVA-bath photochemotherapy and isotretinoin in sclerodermatous graft-versus-host disease
Kamran Ghoreschi et al.
EUROPEAN JOURNAL OF DERMATOLOGY (2008)
IL-33 can promote survival, adhesion and cytokine production in human mast cells
Motoyasu Iikura et al.
LABORATORY INVESTIGATION (2007)
Oral biopsies from patients with orofacial granulomatosis with histology resembling Crohn's disease have a prominent Th1 environment
Jona Freysdottir et al.
INFLAMMATORY BOWEL DISEASES (2007)
Activation of the STAT1 signalling pathway in lupus nephritis in MRL/lpr mice
J. Dong et al.
LUPUS (2007)
Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity
Yoshiyuki Minegishi et al.
IMMUNITY (2006)
Type I interferon-associated cytotoxic inflammation in lichen planus
Joerg Wenzel et al.
JOURNAL OF CUTANEOUS PATHOLOGY (2006)
Profile of 513 patients with alopecia areata: associations of disease subtypes with atopy, autoimmune disease and positive family history
C. Goh et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2006)
STAT4 deficiency reduces autoantibody production and glomerulonephritis in a mouse model of lupus
Zhiwei Xu et al.
CLINICAL IMMUNOLOGY (2006)
Clindamycin and rifampicin combination therapy for hidradenitis suppurativa
CO Mendonça et al.
BRITISH JOURNAL OF DERMATOLOGY (2006)
Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease
E Zorn et al.
BLOOD (2005)
Interferon-α/β-mediated innate immune mechanisms in dermatomyositis
SA Greenberg et al.
ANNALS OF NEUROLOGY (2005)
Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs
M Pesu et al.
IMMUNOLOGICAL REVIEWS (2005)
Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model
S Sano et al.
NATURE MEDICINE (2005)
Topical tacrolimus therapy for vitiligio: Therapeutic responses and skin messenger RNA expression of proinflammatory cytokines
PE Grimes et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2004)
Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic cell transplantation
M Lin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Immunopolarization of CD4+ and CD8+ T cells to type-1-like is associated with melanocyte loss in human vitiligo
A Wankowicz-Kalinska et al.
LABORATORY INVESTIGATION (2003)
Successful treatment of granulomatous cheilitis with thalidomide
P Thomas et al.
ARCHIVES OF DERMATOLOGY (2003)
Molecular profiles of inflammatory myopathies
SA Greenberg et al.
NEUROLOGY (2002)
Interferon-γ and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation
J Cavet et al.
BLOOD (2001)
Partial impairment of cytokine responses in Tyk2-deficient mice
M Karaghiosoff et al.
IMMUNITY (2000)
Share Paper
